Abstract

Autologous T cells engineered to express a chimeric antigen receptor (CAR) remain poorly effective against solid tumors, partly because solid neoplasms can establish an immunosuppressive microenvironment. Recent findings by Srivastava et al. suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.

Original languageEnglish
Pages (from-to)179-181
Number of pages3
JournalTrends in Cancer
Volume7
Issue number3
DOIs
StatePublished - Mar 2021
Externally publishedYes

Keywords

  • KP mice
  • ROR1
  • cyclophosphamide
  • lung adenocarcinoma
  • radiation therapy
  • tumor-associated macrophages
  • T-Lymphocytes
  • Humans
  • Receptors, Chimeric Antigen
  • Tumor Microenvironment
  • Neoplasms

Fingerprint

Dive into the research topics of 'Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy'. Together they form a unique fingerprint.

Cite this